Busey Wealth Management trimmed its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 0.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,807 shares of the company’s stock after selling 160 shares during the period. Busey Wealth Management’s holdings in Eli Lilly And Co were worth $3,089,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Trust Department MB Financial Bank N A boosted its position in Eli Lilly And Co by 54.7% in the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares during the last quarter. Captrust Financial Advisors boosted its position in Eli Lilly And Co by 0.4% in the 4th quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after buying an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in Eli Lilly And Co by 1.6% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock valued at $641,000 after buying an additional 87 shares during the last quarter. First Personal Financial Services boosted its position in Eli Lilly And Co by 2.3% in the 4th quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock valued at $455,000 after buying an additional 89 shares during the last quarter. Finally, Carroll Financial Associates Inc. boosted its position in Eli Lilly And Co by 1.3% in the 4th quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock valued at $810,000 after buying an additional 91 shares during the last quarter. 79.58% of the stock is owned by hedge funds and other institutional investors.

NYSE:LLY opened at $115.20 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. The firm has a market capitalization of $119.33 billion, a PE ratio of 20.76, a P/E/G ratio of 2.35 and a beta of 0.33. Eli Lilly And Co has a 12-month low of $77.09 and a 12-month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. Analysts forecast that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

Several research firms have recently issued reports on LLY. UBS Group reduced their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. Argus restated a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Barclays restated a “buy” rating and issued a $130.00 price target on shares of Eli Lilly And Co in a research report on Sunday, January 20th. Finally, Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a research report on Wednesday, April 10th. Ten analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $118.02.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $131.41, for a total transaction of $26,939,050.00. Following the transaction, the insider now directly owns 116,814,018 shares in the company, valued at $15,350,530,105.38. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 1,000 shares of Eli Lilly And Co stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 867,382 shares of company stock worth $109,265,182. Corporate insiders own 0.11% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://theolympiareport.com/2019/04/20/eli-lilly-and-co-lly-position-trimmed-by-busey-wealth-management.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Day Trading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.